Letters to the Editor

A phase II study of ponatinib for prevention of relapse after allotransplantation in FLT3 internal tandem duplication mutation positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial

Hematology Department, Nantes University Hospital, Nantes, France; INSERM UMR1232, CRCINA IRS-UN, University of Nantes
Hematology Department, Grenoble University Hospital, Grenoble
Hematology Department, Angers University Hospital, Angers
Hematology Department, Caen University Hospital, Caen
Hematology Department, Nancy University Hospital, Nancy
Hematology Department, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite
Hematology Department, Hôpital St-Antoine, AP-HP, Paris
Hematology Department, Poitiers University Hospital, Poitiers
Hematology Department, IUCT Oncopole, Toulouse
Hematology Department, Lille University Hospital, Lille
Hematology Department, Nantes University Hospital, Nantes
Hematology Department, Nantes University Hospital, Nantes
Hematology Department, Nantes University Hospital, Nantes
Hematology Department, Nantes University Hospital, Nantes
Hematology Department, Nantes University Hospital, Nantes, France; INSERM UMR1232, CRCINA IRS-UN, University of Nantes
Haematologica Early view Apr 17, 2025 https://doi.org/10.3324/haematol.2025.287681